Credit Suisse’s Xeris Biopharma Holdings XERS Stock Holding History

Credit Suisse’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$7	–	3760
2022 Q4	$7	Sell	5 -752	-99%	-$1.06K	﹤0.01%	3784
2022 Q3	$1K	Buy	757 +692	+1,065%	+$1.14K	﹤0.01%	3948
2022 Q2	$0	Buy	+65	New	+$137	﹤0.01%	4365
2021 Q2	–	Sell	-10,601	Closed	-$48K	–	4635
2021 Q1	$48K	Sell	10,601 -508	-5%	-$2.74K	﹤0.01%	4228
2020 Q4	$55K	Buy	+11,109	New	+$55.6K	﹤0.01%	4247

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Credit Suisse's XERS Position: Q1 2023 in Review

Credit Suisse sold out of Xeris Biopharma Holdings (XERS) in Q1 2023, closing a stake of 5 shares — an estimated $7 sold.

Credit Suisse first reported a position in XERS in Q4 2020 and held it in 5 quarters. The position peaked at $55K in Q4 2020. 92 funds tracked by Wall St. Rank hold XERS as of Q1 2023.

Credit Suisse reported no remaining Xeris Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 5 Xeris Biopharma Holdings shares in Q1 2023, an estimated $7.
Credit Suisse first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 5 quarters.
Credit Suisse's Xeris Biopharma Holdings position peaked at $55K in Q4 2020.
92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.